^
    Back
    Association details:
    Biomarker:EZH2 Y646
    Cancer:Melanoma
    Drug:GSK2816126 (EZH2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Oncotarget
    Title:

    Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes

    Excerpt:
    The EZH2Y646 mutant cell lines were the most sensitive to GSK126 inhibition ranging from 3.2–8.0 μM...
    DOI:
    10.18632/oncotarget.4809